Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials

Depression and Anxiety

Volumn 33, Issue 10, 2016, Pages 895-906

  Carlezon, William A ^a   Krystal, Andrew D ^b  

^a MCLEAN HOSPITAL   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anxiety; anxiety disorders; mood disorders; pharmacotherapy; substance use disorders; treatment

Indexed keywords

2 (3,4 DICHLOROPHENYL) N METHYL N [1 (3 ISOTHIOCYANATOPHENYL) 2 (1 PYRROLIDINYL)ETHYL]ACETAMIDE; 2 METHYL N ((2' (PYRROLIDIN 1 YLSULFONYL)BIPHENYL 4 YL)METHYL)PROPAN 1 AMINE; 3 [[(3 ENDO) 8 ((5 METHYL 2 THIENYL)METHYL) 8 AZABICYCLO[3.2.1]OCT 3 YL]OXY]BENZAMIDE; 4 [4 ((2 (3,5 DIMETHYLPHENYL) 1 PYRROLIDINYL)METHYL)PHENOXY] 3 FLUOROBENZAMIDE; 5' GUANIDINONALTRINDOLE; 7 HYDROXY N [1 (4 (3 HYDROXYPHENYL) 3,4 DIMETHYLPIPERIDIN 1 YL) 3 METHYLBUTAN 2 YL] 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBOXAMIDE; ARODYN; BUPRENORPHINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DYNORPHIN; IMIPRAMINE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; NALTREXONE; NORBINALTORPHIMINE; PLACEBO; SAMIDORPHAN; TRANS 2 ISOTHIOCYANATO 4,5 DICHLORO N METHYL N (2 (1 PYRROLIDINYL)CYCLOHEXYL)BENZENEACETAMIDE; UNCLASSIFIED DRUG; ZYKLOPHIN;

ALCOHOLISM; ANTIDEPRESSANT ACTIVITY; ANXIETY DISORDER; ARTICLE; CLINICAL RESEARCH; CLINICAL STUDY; COCAINE DEPENDENCE; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; MENTAL DISEASE; MENTAL STRESS; MOOD DISORDER; NONHUMAN; NUCLEUS ACCUMBENS; OPIATE ADDICTION; PRIORITY JOURNAL; REWARD; TRANQUILIZING ACTIVITY; TRANSLATIONAL RESEARCH; TREATMENT RESISTANT DEPRESSION; UPREGULATION;

EID: 84991045189     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22500     Document Type: Article

References (103)

1. Nestler EJ, Carlzon WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006;59:1151–1159.
2. Carlezon WA, Duman RS, Nestler EJ. The many faces of CREB. Trends Neurosci 2005;28:436–445.
3. Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand of the κ opioid receptor. Science 1982;215:413–415. doi:10.1016/0304-3959(82)90120-8.
4. Bruchas MR, Land BB, Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 2010;1314:44–55. doi:10.1016/j.brainres.2009.08.062.
5. Knoll AT, Carlezon WA. Dynorphin, stress, and depression. Brain Res 2010;1314:56–73. doi:10.1016/j.brainres.2009.09.074.
6. Carroll FI, Carlezon William AJ. Development of κ opioid receptor antagonists. J Med Chem 2013;56:2178–2195. doi:10.1021/jm301783x.
7. Van't Veer A, Carlezon WA. Role of kappa-opioid receptors in stress and anxiety-related behavior. Psychopharmacology (Berl) 2013;229:435–452. doi:10.1007/s00213-013-3195-5.
8. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 1996;16:2365–2372.
9. Chen ACH, Shirayama Y, Shin KH, et al. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry 2001;49:753–762. doi:10.1016/S0006-3223(00)01114-8.
10. Dranovsky A, Hen R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry 2006;59:1136–1143. doi:10.1016/j.biopsych.2006.03.082.
11. Turgeon SM, Pollack AE, Fink JS. Enhanced CREB phosphorylation and changes in c-Fos and FRA expression in striatum accompany amphetamine sensitization. Brain Res 1997;749:120–126. doi:10.1016/S0006-8993(96)01316-9.
12. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug-induced and stress-induced sensitization of motor-activity. Brain Res Rev 1991;16:223–244. doi:10.1016/0165-0173(91)90007-U.
13. Lett BT. Repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine, and cocaine. Psychopharmacology (Berl) 1989;98:357–362. doi:10.1007/BF00451687.
14. Carlezon WA, Thome J, Olson VG, et al. Regulation of cocaine reward by CREB. Science (80-) 1998;282:2272–2275. doi:10.1126/science.282.5397.2272.
15. Pliakas AM, Carlson RR, Neve RL, et al. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J Neurosci 2001;21:7397–7403. doi:21/18/7397 [pii].
16. Kelz MB, Chen J, Carlezon WA, Jr., et al. Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine. Nature 1999;401:272–276. doi:10.1038/45790.
17. Pfeiffer A, Brantl V, Herz A, et al. Psychotomimesis mediated by kappa opiate receptors. Science (80-) 1986;233:774–776. doi:10.1126/science.3016896.
18. Walsh SL, Strain EC, Abreu ME, et al. Enadoline, a selective kappa opioid agonist: Comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 2001;157:151–162. doi:10.1007/s002130100788.
19. Bals-Kubik R, Ableitner A, Herz A, et al. Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 1993;264:489–495.
20. Chartoff EH, Papadopoulou M, MacDonald ML, et al. Desipramine reduces stress-activated dynorphin expression and CREB phosphorylation in NAc tissue. Mol Pharmacol 2009;75:704–712. doi:10.1124/mol.108.051417.
21. Newton SS, Thome J, Wallace TL, et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci 2002;22:10883–10890. doi: 22/24/10883 [pii].
22. Mague SD, Pliakas AM, Todtenkopf MS, et al. Antidepressant-like effects of κ-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 2003;305:323–330.
23. Beardsley PM, Howard JL, Shelton KL, et al. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) 2005;183:118–126. doi:10.1007/s00213-005-0167-4.
24. Shirayama Y, Ishida H, Iwata M, et al. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem 2004;90:1258–1268. doi:10.1111/j.1471-4159.2004.02589.x.
25. Muschamp JW, Van't Veer A, Parsegian A, et al. Activation of CREB in the nucleus accumbens shell produces anhedonia and resistance to extinction of fear in rats. J Neurosci 2011;31:3095–3103. doi:10.1523/JNEUROSCI.5973-10.2011.
26. Donahue RJ, Landino SM, Golden SA, et al. Effects of acute and chronic social defeat stress are differentially mediated by the dynorphin/kappa-opioid receptor system. Behav Pharmacol 2015;26:654–663. doi:10.1097/FBP.0000000000000155.
27. Bruchas MR, Land BB, Lemos JC, et al. CRF1-R activation of the dynorphin/kappa opioid system in the mouse basolateral amygdala mediates anxiety-like behavior. PLoS One 2009;4:e8528. doi:10.1371/journal.pone.0008528.
28. Carlezon WA. Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther 2009;123:334–343.
29. Knoll AT, Meloni EG, Thomas JB, et al. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 2007;323:838–845. doi:10.1124/jpet.107.127415.
30. Knoll AT, Muschamp JW, Sillivan SE, et al. Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats. Biol Psychiatry 2011;70:425–433. doi:10.1016/j.biopsych.2011.03.017.
31. Bagdy G, Graf M, Anheuer ZE, et al. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 2001;4:399–408. doi:10.1017/S1461145701002632.
32. Drapier D, Bentué-Ferrer D, Laviolle B, et al. Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze. Behav Brain Res 2007;176:202–209. doi:10.1016/j.bbr.2006.10.002.
33. Endoh T, Matsuura H, Tanaka C, et al. Nor-binaltorphimine: a potent and selective k-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Thér 1992;316:30–42.
34. Melief EJ, Miyatake M, Carroll FI, et al. Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol Pharmacol 2011;80:920–929. doi:10.1124/mol.111.074195.
35. Mahan AL, Ressler KJ. Fear conditioning, synpatic plasticity, and the amygdala: implications for posttraumatic stress disorder. Trends Neurosci 2013;35:24–35. doi:10.1016/j.tins.2011.06.007.Fear.
36. Chartoff E, Sawyer A, Rachlin A, et al. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology 2012;62:167–176. doi:10.1016/j.neuropharm.2011.06.014.
37. Schank JR, Goldstein AL, Rowe KE, et al. The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety. Addict Biol 2012;17:634–647. doi:10.1111/j.1369-1600.2012.00455.x.
38. Van't Veer A, Yano JM, Carroll FI, et al. Corticotropin-releasing factor (CRF)-induced disruption of attention in rats is blocked by the κ-opioid receptor antagonist JDTic. Neuropsychopharmacology 2012;2809–2816. doi:10.1038/npp.2012.151.
39. Beard C, Donahue RJ, Dillon DG, et al. Abnormal error processing in depressive states: a translational examination in humans and rats. Transl Psychiatry 2015;5:e564. doi:10.1038/tp.2015.54.
40. Carlezon WA, George TP. Circumspectives: the promise of ketamine. Neuropsychopharmacology 2015;40:257–258.
41. Carlezon WA, Chartoff E. Perspective: Progress on the study and treatment of depressive illness. Neuropsychopharmacology 2009;34:1361–1362. doi:10.1038/npp.2009.16.
42. Muschamp JW, Carlezon WA. Roles of nucleus accumbens CREB and dynorphin in dysregulation of motivation. Cold Spring Harb Perspect Med 2013;3:a012005. doi:10.1101/cshperspect.a012005.
43. Svingos AL, Colago EE, Pickel VM. Cellular sites for dynorphin activation of κ-opioid receptors in the rat nucleus accumbens shell. J Neurosci 1999;19:1804–1813.
44. Svingos AL, Chavkin C, Colago EEO, et al. Major coexpression of κ-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 2001;42:185–192. doi:10.1002/syn.10005.
45. Donzanti BA, Althaus JS, Payson MM, et al. Kappa agonist-induced reduction in dopamine release: site of action and tolerance. Res Commun Chem Pathol Pharmacol 1992;78:193–210.
46. Carlezon WA, Béguin C, DiNieri JA, et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther 2006;316:440–447. doi:10.1124/jpet.105.092304.
47. Reis FLV, Masson S, De Oliveira AR, et al. Dopaminergic mechanisms in the conditioned and unconditioned fear as assessed by the two-way avoidance and light switch-off tests. Pharmacol Biochem Behav 2004;79:359–365. doi:10.1016/j.pbb.2004.08.006.
48. Carlezon WA, Thomas MJ. Biological substrates of reward and aversion: A nucleus accumbens activity hypothesis. Neuropharmacology 2009;56:122–132. doi:10.1016/j.neuropharm.2008.06.075.
49. Schwaninger M, Schöfl C, Blume R, et al. Inhibition by antidepressant drugs of cyclic AMP response element-binding protein/cyclic AMP response element-directed gene transcription. Mol Pharmacol 1995;47:1112–1118.
50. Tejeda HA, Counotte DS, Oh E, et al. Prefrontal cortical kappa-opioid receptor modulation of local neurotransmission and conditioned place aversion. Neuropsychopharmacology 2013;38:1770–1779. doi:10.1038/npp.2013.76.
51. Wise RA. Brain dopamine and reward. Annu Rev Psychol 1989;40:191–225. doi:10.1146/annurev.psych.40.1.191.
52. Todtenkopf M, Marcus JF, Portoghese PS, Carlezon WA Jr. Effects of κ-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology 2004;172:463–470.
53. Wise RA. Drug-activation of brain reward pathways. Drug Alcohol Depend 1998;51:13–22. doi:10.1016/S0376-8716(98)00063-5.
54. Carlezon WA, Chartoff EH. Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc 2007;2:2987–2995. doi:10.1038/nprot.2007.441.
55. Maisonneuve IM, Archer S, Glick SD. U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett 1994;181:57–60.
56. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988;85:5274–5278. doi:10.1073/pnas.85.14.5274.
57. Spanagel R, Shippenberg TS. Modulation of morphine-induced sensitization by endogenous κ-opioid systems in the rat. Neurosci Lett 1993;153:232–236. doi:10.1016/0304-3940(93)90329-J.
58. Potter DN, Damez-Werno D, Carlezon WA, Jr., et al. Repeated exposure to the kappa-opioid receptor agonist salvinorin A modulates extracellular signal-regulated kinase and reward sensitivity. Biol Psychiatry 2011;70:744–753. doi:10.1016/j.biopsych.2011.05.021.
59. Urbano M, Guerrero M, Rosen H, et al. Antagonists of the kappa opioid receptor. Bioorg Med Chem Lett 2014;24:2021–2032. doi:10.1016/j.bmcl.2014.03.040.
60. Rorick-Kehn LM, Witkin JM, Statnick MA, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology 2014;77:131–144. doi:10.1016/j.neuropharm.2013.09.021.
61. Allain F, Minogianis EA, Roberts DCS, et al. How fast and how often: the pharmacokinetics of drug use are decisive in addiction. Neurosci Biobehav Rev 2015;56:166–179. doi:10.1016/j.neubiorev.2015.06.012.
62. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010;167:748–751. doi:10.1176/appi.ajp.2010.09091379.
63. Tomasiewicz HC, Todtenkopf MS, Chartoff EH, et al. The κ-opioid agonist U69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry 2008;64:982–988. doi:10.1016/j.biopsych.2008.05.029.
64. Bruijnzeel AW. kappa-Opioid receptor signaling and brain reward function. Brain Res Rev 2009;62:127–146. doi:10.1016/j.brainresrev.2009.09.008.
65. Ebner SR, Roitman MF, Potter DN, et al. Depressive-like effects of the kappa opioid receptor agonist salvinorin A are associated with decreased phasic dopamine release in the nucleus accumbens. Psychopharmacology (Berl) 2010;209:241–252. doi:10.1007/s00213-010-1836-5.
66. Wee S, Koob GF. The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) 2010;210:121–135. doi:10.1007/s00213-010-1825-8.
67. Land BB, Bruchas MR, Lemos JC, et al. The dysphoric component of stress is encoded by activation of the dynorphin κ-opioid system. J Neurosci 2008;28:407–414. doi:10.1523/JNEUROSCI.4458-07.2008.
68. Peters MF, Zacco A, Gordon J, et al. Identification of short-acting κ-opioid receptor antagonists with anxiolytic-like activity. Eur J Pharmacol 2011;661:27–34. doi:10.1016/j.ejphar.2011.04.017.
69. Schindler AG, Messinger DI, Smith JS, et al. Stress produces aversion and potentiates cocaine reward by releasing endogenous dynorphins in the ventral striatum to locally stimulate serotonin reuptake. J Neurosci 2012;32:17582–17596. doi:10.1523/JNEUROSCI.3220-12.2012.
70. Carr GV, Lucki I. Comparison of the kappa-opioid receptor antagonist DIPPA in tests of anxiety-like behavior between wistar kyoto and sprague dawley rats. Psychopharmacology (Berl) 2010;209:295–302. doi:10.1007/s00213-010-1832-9.
71. Carroll FI, Harris LS, Aceto MD. Effects of JDTic, a selective κ-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model. Eur J Pharmacol 2005;524:89–94. doi:10.1016/j.ejphar.2005.09.013.
72. Jones RM, Portoghese PS. 5’-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. Eur J Pharmacol 2000;396:49–52.
73. Negus SS, Mello NK, Linsenmayer DC, et al. Kappa opioid antagonist effects of the novel kappa antagonist 5’-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys. Psychopharmacology (Berl) 2002;163:412–419.
74. Walker BM, Koob GF. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 2008;33:643–652. doi:10.1038/sj.npp.1301438.
75. Grimwood S, Lu Y, Schmidt AW, et al. Pharmacological characterization of 2-methyl-N-((2’-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors. J Pharmacol Exp Ther 2011;339:555–566. doi:10.1124/jpet.111.185108.
76. Carey AN, Borozny K, Aldrich JV, et al. Reinstatement of cocaine place-conditioning prevented by the peptide kappa-opioid receptor antagonist arodyn. Eur J Pharmacol 2007;569:84–89. doi:10.1016/j.ejphar.2007.05.007.
77. Aldrich JV, Patkar KA, McLaughlin JP. Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proc Natl Acad Sci U S A 2009;106:18396–18401. doi:0910180106 [pii]\r10.1073/pnas.0910180106.
78. Emrich HM, Vogt P, Herz A, et al. Antidepressant effects of buprenorphine. Lancet 1982;2:709. doi:S0140-6736(82)90727-9 [pii].
79. Khroyan TV, Wu J, Polgar WE, et al. BU08073 a buprenorphine analog with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice. Br J Pharmacol 2015;172:668–680. doi:10.1111/bph.12796.
80. Ducharme S, Fraser R, Gill K. Update on the clinical use of buprenorphine: in opioid-related disorders. Can Fam Physician 2012;58:37–41.
81. Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;2:CD002207. doi:10.1002/14651858.CD002207.pub4.Copyright.
82. Falcon E, Maier K, Robinson SA, et al. Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology (Berl) 2015;232:907–915. doi:10.1007/s00213-014-3723-y.
83. Browne CA, van Nest DS, Lucki I. Antidepressant-like effects of buprenorphine in rats are strain dependent. Behav Brain Res 2015;278:385–392. doi:10.1016/j.bbr.2014.10.014.
84. Wee S, Vendruscolo LF, Misra KK, et al. A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence. Sci Transl Med 2012;4:146ra110. doi:10.1126/scitranslmed.3003948.
85. Cordery SF, Taverner A, Ridzwan IE, et al. A non-rewarding, non-aversive buprenorphine/naltrexone combination attenuates drug-primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm. Addict Biol 2014;19:575–586. doi:10.1111/adb.12020.
86. Almatroudi A, Husbands SM, Bailey CP, et al. Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice. J Psychopharmacol 2015;29:812–821. doi:10.1177/0269881115586937.
87. Buda JJ, Carroll FI, Kosten TR, et al. A double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetics of single, escalating oral doses of JDTic. Neuropsychopharmacology 2015;40:2059–2065.
88. Kosten TR, Kleber HD, Morgan C. Treatment of cocaine abuse with buprenorphine. Biol Psychiatry 1989;26:637–639. doi:10.1016/0006-3223(89)90090-5.
89. Schottenfeld RS, Pakes JR, Oliveto A, et al. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997;54:713–720. doi:10.1001/archpsyc.1997.01830200041006.
90. Montoya ID, Gorelick DA, Preston KL, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 2004;75:34–38. doi:10.1016/j.clpt.2003.09.004.
91. Bodkin JA, Zornberg GL, Lukas SE, et al. Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 1995;15:49–57. doi:10.1097/00004714-199502000-00008.
92. Nyhuis PW, Gastpar M, Scherbaum N. Opiate treatment in depression refractory to antidepressants and electroconvulsive therapy. J Clin Psychopharmacol 2008;28:593–595. doi:10.1097/JCP.0b013e31818638a4.
93. Karp JF, Butters MA, Begley AE, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry 2014;75:e785–93. doi:10.4088/JCP.13m08725.
94. Bershad AK, Jaffe JH, Childs E, et al. Opioid partial agonist buprenorphine dampens responses to psychosocial stress in humans. Psychoneuroendocrinology 2015;52:281–288. doi:10.1016/j.psyneuen.2014.12.004.
95. Yovell Y, Bar G, Mashiah M, et al. Ultra-low-dose buprenorphine as a time-limited treatment for severe suicidal ideation: a randomized controlled trial. Am J Psychiatry 2015;appiajp201515040535.
96. McCann DJ. Potential of buprenorphine/naltrexone in treating polydrug addiction and co-occurring psychiatric disorders. Clin Pharmacol Ther 2008;83:627–630. doi:10.1038/sj.clpt.6100503.
97. Rothman RB, Gorelick DA, Heishman SJ, et al. An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence. J Subst Abuse Treat 2000;18:277–281.
98. Gerra G, Fantoma A, Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 2006;20:806–814. doi:10.1177/0269881106060835.
99. Ehrich E, Turncliff R, Du Y, et al. Evaluation of opioid modulation in major depressive disorder. Neuropsychopharmacology 2014;40:1–8. doi:10.1038/npp.2014.330.
100. Insel TR, Scolnick EM. Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry 2006;11:11–17. doi:10.1038/sj.mp.4001777.
101. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9:203–214. doi:10.1038/nrd3078.
102. Bennett MA, Murray TF, Aldrich JV. Structure–activity relationships of arodyn, a novel acetylated kappa opioid receptor antagonist. J Pept Res 2005;65:322–332.
103. Stevens WC, Jones RM, Subramanian G, et al. Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J Med Chem 2000;43:2759–2769. doi:10.1021/jm0000665.